Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) has completed establishing a wholly-owned subsidiary in Japan to support potential direct commercialization of QRX003 for Netherton Syndrome, if approved.
QRX003 has Orphan Drug Designation in the US, EU, and Japan, is in Phase 2 trials, with Phase 3 planned for 2H 2026 and a potential NDA in 2027.
Positive
- Wholly-owned Japanese subsidiary established to support QRX003 commercialization
- QRX003 holds Orphan Drug Designation in US, EU, and Japan
- Nine commercial partnerships for QRX003 covering sixty one countries
- QRX003 in Phase 2 trials; pivotal Phase 3 planned for 2H 2026
- Potential QRX003 NDA filing targeted for 2027
- Direct self-commercialization strategy in US, Western Europe, and Japan
Negative
- QRX003 not yet approved; still in clinical development stages
- Pivotal Phase 3 study and regulatory reviews remain ahead before any launch
News Market Reaction – QNRX
In the Jun 18 session, QNRX gained 0.65%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Clinical update | Positive | -4.1% | Pediatric compassionate use data showed improvements without treatment-related adverse events. |
| Jun 04 | Regulatory win | Positive | -3.2% | Japan MHLW granted Orphan Drug Designation for QRX003 in Netherton Syndrome. |
| Jun 02 | Pipeline expansion | Positive | -4.4% | IND filed for QRX003 in Peeling Skin Syndrome, enabling a Phase 2 trial. |
| May 07 | Earnings & update | Neutral | -0.9% | Q1 2026 results with wider loss but significant regulatory progress for QRX003 and QRX009. |
| Apr 30 | Earnings date set | Neutral | +9.3% | Announcement of timing for Q1 2026 corporate update and financial results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory updates have often been followed by negative next-day price reactions.
Key Terms
orphan drug designation regulatory
netherton syndrome medical
phase 2 clinical
phase 3 clinical
nda filing regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories
Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW
ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan’s Ministry of Health, Labour and Welfare (MHLW) and supports Quoin’s long-term commercial plans in one of its three core markets.
A local corporate presence allows Quoin to engage directly with Japanese regulators, clinicians, and patient advocacy organizations as it builds the commercial infrastructure to support a potential launch. Japan is one of Quoin’s core territories, along with the United States and Western Europe, in which Quoin intends to self-commercialize QRX003 and its other pipeline products. Outside of these territories, Quoin has established nine commercial partnerships for QRX003 spanning sixty one countries, which combined with the company’s core territories, could facilitate almost global availability of the product if approved.
QRX003 has now received Orphan Drug Designation for Netherton Syndrome in the United States, the European Union, and Japan, providing development and commercial incentives across all three of Quoin’s core commercial territories.
“Establishing our Japanese subsidiary is another important step forward in our plan to self-commercialize QRX003 in one of our three core markets and follows the earlier establishment of Quoin Therapeutics, Ireland, our Western European subsidiary,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “With Orphan Drug Designation now secured in the United States, Europe, and Japan, we are continuing to build the commercial infrastructure in advance of a potential approval. Establishing our presence in Japan now reflects both our confidence in QRX003 and our long-term commitment to this very attractive market.”
QRX003 lotion (
About Netherton Syndrome
Netherton Syndrome is a rare, inherited skin disorder caused by mutations in the SPINK5 gene, leading to severe skin barrier dysfunction, chronic inflammation, and a heightened risk of infections and allergic complications. Patients often experience widespread skin redness, scaling, persistent itching, and significant impairment in quality of life. There are currently no FDA-approved therapies for the treatment of Netherton Syndrome, and treatment options are limited to supportive care and off-label therapies.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Forward-Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin’s strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved; engaging directly with Japanese regulators, clinicians, and patient advocacy organizations as Quoin builds the commercial infrastructure to support a potential launch; self-commercializing QRX003 and the Company’s other pipeline products in Japan, the United States and Western Europe; facilitating almost global availability of the product if approved; continuing to build the commercial infrastructure in advance of a potential approval; initiating Quoin’s pivotal Phase 3 study in the second half of 2026, with a potential NDA filing in 2027; QRX003 having the potential to become the first approved treatment for Netherton Syndrome; working closely with leading Japanese clinicians to refine the clinical and regulatory pathway for approval of QRX003 for the treatment of Netherton Syndrome; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
